ValMo Trend Following Series - June 2021
For those of you who didn't see the introductory blog to this series, you can find it here.
In this blog (above) I take you through how I intend to beat the passive 'buy and hold' approach to investing by trading a low maintenance spread betting system for buying shares - in effect starting a Spread ISA, as Robbie 'Naked Trader' Burns coined it in his books.
ValMo refers to 'Value/Momentum' stocks. Trend following means that we're looking to capture long term bullish trends on UK stocks. Spread betting means (to UK peeps) that we're doing this all tax-free (like an extension to your ISA).
I intend to share every single trade on this website for you guys to follow along, or even copy. ("Always read the label")
To stay abreast of new positions and track record to date please visit: ValMo Trades Page.
Starting Funds: £5,000
Account Equity: £5,251 Margin Used: £1,357 Margin Available: £3,893
Closed Net P&L: -£101.65 Average Loss: -£33.88
Worst Loss: -£47.43
June 2021 Trades
So our Value/Momentum Stockopedia screener has shortlisted the following UK stocks for us to trade.
As you can see from the chart, this initial selection of companies if traded (in equal measure) over the last 12 months would have returned +25.36% profit vs. +13.02% from the benchmark FTSE All Share Index over the same period.
So that should give us some confidence in the edge that this system could provide us with.
(Past performance does not guarantee future returns, it is just an indicative idea based on real historical data, may contain nuts).
Closed Trades From May
As you can see from the chart below the price closed below the 200 EMA, and so as per our system, we exited that position and will add in a new one that qualifies for our screener (see options further below).
New Trades For June
To remain informed of new positions and track record to date please visit: ValMo Trades Page.
Ovid Therapeutics Inc - BUY £1.15p @ 437
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Ex-Dividend Date: N/A
Old National Bancorp- BUY £0.33p @ 1924
Old National Bancorp is a financial holding company. The Company, through its banking subsidiary, provides a range of services, including commercial and consumer loan and depository services, private banking, brokerage, trust, investment advisory and other traditional banking services. The Company focuses on community banking. The Company's banking segment operates through its subsidiary, Old National Bank. As of December 31, 2016, Old National Bank operated approximately 203 banking centers located in Indiana, Kentucky, Michigan and Wisconsin. As of December 31, 2016, Old National Bank leased 81 banking centers from unaffiliated third parties. Each of the branches of Old National Bank provide a group of similar community banking services, including products and services, such as commercial, real estate and consumer loans, time deposits, checking and savings accounts, cash management, brokerage, trust and investment advisory services.
Ex-Dividend Date: N/A
Again, to stay on top of new positions and track record to date please visit: ValMo Trades Page.
Below is a glance at the screenshots of how each trade is currently trading: